Last updated: February 15, 2026
What is the current development status of PF-04457845?
PF-04457845 is a selective antagonist targeting soluble epoxide hydrolase (sEH). Its primary application concerns inflammatory and cardiovascular conditions due to the enzyme's role in regulating lipid mediators. The compound was developed by Pfizer and entered clinical evaluation phases but has not progressed beyond early trials.
Clinical development phases
- Phase 1 trials: PF-04457845 advanced into Phase 1, assessing safety, tolerability, and pharmacokinetics in healthy volunteers.
- Phase 2 trials: No publicly available data indicates progression into Phase 2, suggesting that further development was halted or shelved.
- Trials status: As of 2023, no ongoing or planned clinical trials are registered under PF-04457845 on ClinicalTrials.gov or other major registries.
Regulatory status
- PF-04457845 has not received regulatory approval nor has it entered a New Drug Application process, indicating early-stage development or preclinical cessation.
How does PF-04457845 compare with other sEH inhibitors?
| Feature |
PF-04457845 |
Other sEH inhibitors |
| Development stage |
Phase 1 (completed) |
Mostly preclinical or early clinical |
| Clinical trial data |
Limited; no results publicly released |
Varies; some have published phase 1 or 2 data |
| Main focus |
Cardiovascular inflammation |
Aspects of pain, neuroinflammation, metabolic disorders |
| Pharmacokinetic profile |
Favorable in early studies |
Varies, some with limited bioavailability |
What are the market prospects for sEH inhibitors like PF-04457845?
The sEH inhibitor class presents potential for treating chronic inflammation, hypertension, and metabolic diseases. Yet, failure or stagnation in clinical development constrains commercial outlook.
Market size and trends
- Current indications: Predominantly under investigation; no approved drugs specifically targeting sEH.
- Estimated market: The global inflammation therapeutics market was valued at approximately $65 billion in 2022, with niche segments targeting lipid mediators forecasted to grow modestly.
- Pipeline activity: Few candidates advanced past early trials; many discontinued due to safety or efficacy concerns.
Competitor analysis
- Several firms, including Merck and GlaxoSmithKline, explored sEH inhibitors; most projects halted after mixed clinical results.
- Pfizer’s withdrawal from PF-04457845 suggests limited commercial viability or strategic reprioritization.
Regulatory challenges
- Past sEH inhibitor candidates faced safety issues or inconsistent efficacy signals.
- Regulatory agencies demand robust evidence of benefit in well-defined patient populations.
Market projection
- Without active development or pipeline entrants, the sEH inhibitor market remains theoretical.
- For PF-04457845: market entry unlikely in the foreseeable future unless new positive data emerges.
- Broader lipid mediator modulation therapies are more active but face similar hurdles.
Why did development of PF-04457845 stall?
- Clinical data: Limited publicly available efficacy data raises questions about therapeutic benefit.
- Safety concerns: Some preclinical related studies identified off-target effects, though PF-04457845 specifically showed good tolerability in early trials.
- Strategic pivots: Pfizer shifted focus to other therapeutic areas, deprioritizing sEH inhibitors.
- Market considerations: The emerging competition and lack of clear unmet needs for sEH inhibitors diminish incentives.
What are the future considerations?
- Reconsideration of sEH inhibitors relies on novel approaches addressing previous limitations.
- Development of combination therapies might revive interest.
- Biomarker-driven patient selection could improve clinical trial success rates.
- Regulatory pathways require clear demonstration of clinical value over existing therapies.
Key Takeaways
PF-04457845 completed Phase 1 trials but has not advanced into later stages. The sEH inhibitor class exhibits potential but faces challenges in clinical efficacy, safety, and market viability. The drug's development pause reflects broader industry trends of cautious investment amid mixed trial results and limited regulatory incentives. The outlook for PF-04457845 as a commercial drug remains subdued unless new evidence supports renewed development.
FAQs
1. Is PF-04457845 available for clinical use?
No, PF-04457845 has not received regulatory approval and remains in the research phase.
2. Are there ongoing efforts to revive development of PF-04457845?
There are no public indications of active development or plans to restart its clinical program.
3. How do sEH inhibitors compare with other anti-inflammatory drugs?
While they target lipid mediators directly, broad anti-inflammatory agents like NSAIDs have a more extensive clinical track record.
4. What challenges hinder the commercialization of sEH inhibitors?
Clinical efficacy inconsistent across trials, safety concerns, and limited regulatory incentives.
5. Can other sEH inhibitors succeed in the market?
Potential exists in niche indications, but widespread success remains uncertain given current trial outcomes.
Citations:
[1] ClinicalTrials.gov entries and Pfizer pipeline disclosures.
[2] Market research reports on inflammation and lipid mediator therapeutics.
